DETAILS, FICTION AND TRACLEER

6 The phosphodiesterase-five inhibitor sildenafil is licensed for PAH in FC I–IV within the USA and FC II–III in Europe. Endothelin receptor antagonists (ERAs) together with bosentan, sitaxentan and ambrisentan are oral therapies certified for use in PAH. As no oral agent has proven superiority there stays discussion concerning which needs to b